Retrospective Study to Assess the Effect of Telmisartan on Urine Albumin to Creatinine Ratio in Indian Hypertensive Patients

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Information image
Average (ratings)
No ratings
Your rating



Published online:

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Objectives: To assess the impact of telmisartan on urine albumin to creatinine ratio (UACR) and blood pressure (BP) among Indian hypertensive patients on telmisartan monotherapy.

Material and methods: This was a retrospective cohort study. Hypertensive patients prescribed with Telmisartan monotherapy with UACR records of at least two analysable visits were enrolled in the study. The study was approved by an independent ethics committee. The data of enrolled patients was analysed retrospectively to assess the change in UACR and BP from visit one to visit two.

Results: Data of 1,095 patients was available for analysis. The average age was 54.0 ± 11.7 years. There was a significant reduction in UACR from 113.58 ± 443.74 mg/g at visit one to 77.29 ± 326.76 mg/g at visit two (p=0.0012) with telmisartan monotherapy in overall population (mean duration 278 days). Overall 48% patients reverted to normoalbuminuria (UACR<30 mg/g). Reductions in systolic BP and diastolic BP were −8.5 mmHg and −3.8 mmHg, respectively (both p<0.001, mean duration of 99.6 days between visits one and two). The UACR reduced from 83.3 ± 312.4 mg/g at visit one to 58.27 ± 231.47 mg/g at visit two in hypertensive patients with diabetes (n=945, mean duration 292 days). Significant reductions in systolic BP (−8.7 mmHg) and diastolic BP (−3.8 mmHg) were also found in diabetic hypertensive patients (mean duration 101.5 days).

Conclusion: The present study demonstrated that telmisartan monotherapy prevents the progression of microalbuminuria along with causing significant reductions in BP.